Neumora Therapeutics

NMRA

Market cap $386M

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.

Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026 On-track to report data from Phase 1b study of NMRA-511 in Alzheimer's disease agitation around the end of the year $40 million in non-dilutive capital drawn from Neumora's existing facility with K2 HealthVentures Strong financial position with $171.5 million in cash, cash equivalents and marketable securities expected to support operations into 2027 WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in two investor conferences in November.

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs October 27, 2025 8:00 AM EDT Company Participants Helen Rubinstein - Head of Investor Relations Paul Berns Joshua Pinto - President Nicholas Brandon - Chief Scientific Officer Daljit Aurora - Chief Operationg & Development officer Conference Call Participants Myles Minter - William Blair & Company L.L.C., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Douglas Tsao - H.C.

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction  NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215 Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies.

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&D Day on Monday, October 27, 2025, at 8:00 a.m.

WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September.

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development officer - Corporate Participant Helen Rubinstein - Head of Investor Relations Joshua Pinto - President Michael Lee Milligan - CFO & Principal Accounting Officer Nicholas Brandon - Chief Scientific Officer Paul L. Berns - Chairman & CEO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division Douglas Dylan Tsao - H.C.

Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline.